I said US results not FDA. Most of the other stocks that ran hard did it from a lower market cap.
I can't remember now and I have no time to check, but IIRC, the Australian trials were not double-blind, and they were worked on by the inventor, so there's a lack of scientific objectivity. The US trials are double-blind and not touched by the inventor, so they will be reliable.
Ann: ResApp Provides SMARTCOUGH-C May Study Update, page-107
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $176.2M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| RAP (ASX) Chart |
Day chart unavailable